Fibroblast

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Retrieved on: 
måndag, juni 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, ENDO, Endocrinology, GSC, Trial of the century, Aggression, Patient, Thyroid, Signature, Cancer, Intelligence, Thyroid cancer, Thyroid nodule, Prostate cancer, Pathology, Metastasis, B.A, Endocrine Society, Risk, Gene expression, FOLH1, Progression-free survival, Fibroblast, Vanderbilt University Medical Center, Correlation, FNA

“Clinicians generally want to avoid overtreatment of patients with non-aggressive thyroid tumors while targeting more-intensive treatment to those patients with aggressive disease.

Key Points: 
  • “Clinicians generally want to avoid overtreatment of patients with non-aggressive thyroid tumors while targeting more-intensive treatment to those patients with aggressive disease.
  • The challenge is distinguishing between them, especially given the heterogeneity of thyroid tumors,” said Joshua Klopper, M.D., Veracyte’s medical director for Endocrinology.
  • “The studies presented at ENDO 2024 today show how our Research-Use-Only Afirma GRID tool, which leverages our whole-transcriptome-derived testing approach, is helping scientists better understand important nuances in the molecular underpinnings of thyroid tumors.
  • Researchers leveraged the Afirma GRID database to characterize the expression of PSMA (FOLH1) in a cohort of nearly 50,000 thyroid nodules sent for Afirma GSC molecular testing.

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

Retrieved on: 
måndag, maj 20, 2024
MCI, ICI, Patient, CATX, SNMMI, MC1R, Therapy, Neoplasm, EANM, Safety, Society, Nivolumab, ICIS, Melanoma, Cancer, Nuclear medicine, FAP, Fibroblast, NETS, Glomus tumor, Annual general meeting, Pharmaceutical industry

“We are greatly encouraged by the progress of our clinical and preclinical programs," said Thijs Spoor, CEO of Perspective.

Key Points: 
  • “We are greatly encouraged by the progress of our clinical and preclinical programs," said Thijs Spoor, CEO of Perspective.
  • Updates on this trial as of March 7, 2024 were provided during the Company’s investor update on March 18, 2024, accessible on the events page of the Company’s website.
  • This study, in conjunction with the Phase 0 imaging study (NCT05111509), would inform the recommended Phase 2 dose of [212Pb]VMT-α-NET.
  • The most recent prior public update by the investigator was during the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in September 2023.

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
onsdag, maj 15, 2024
Patient, Cohort, BID, Exercise, Therapy, Disease, Safety, Interstitial, Fibroblast, University of Giessen, Biomarker, Acquisition, Șaeș, Fibrosis, Research, IPF, Research and development, Administration, ALRN, Pharmaceutical industry

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
  • The Phase 1b study is ongoing, with topline results from the high-dose cohort expected in the third quarter of 2024.
  • Net Loss: Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023.
  • The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.

FibroBiologics Announces 2024 Annual Meeting of Stockholders

Retrieved on: 
onsdag, maj 15, 2024
Conditional sentence, CDT, Therapy, Shareholder, Fibroblast

HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2024 Annual Meeting of Stockholders will take place on August 27, 2024, at 11 a.m. CDT, exclusively through a virtual format.

Key Points: 
  • HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2024 Annual Meeting of Stockholders will take place on August 27, 2024, at 11 a.m. CDT, exclusively through a virtual format.
  • The record date for determination of stockholders entitled to vote at the annual meeting is July 1, 2024.

FibroBiologics Files 2024 First Quarter Report

Retrieved on: 
tisdag, maj 14, 2024
Conditional sentence, Fibroblast, Therapy, File

HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, with the U.S. Securities and Exchange Commission.

Key Points: 
  • HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, with the U.S. Securities and Exchange Commission.
  • The filing can be viewed through a link on FibroBiologics’ website at https://ir.fibrobiologics.com/sec-filings/quarterly-reports.

FibroBiologics to Present at the BIO International Convention 2024

Retrieved on: 
tisdag, maj 7, 2024
Conditional sentence, PDT, Therapy, Fibroblast, BIO, Pharmaceutical industry

HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a corporate update on recent business and clinical developments at the 2024 BIO International Convention, June 3-6, 2024, in San Diego, California.

Key Points: 
  • HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a corporate update on recent business and clinical developments at the 2024 BIO International Convention, June 3-6, 2024, in San Diego, California.
  • The presentation will occur on Tuesday, June 4, 2024, at 11:45 a.m. PDT in Theater 3.
  • "Since presenting at the BIO International Convention last year, FibroBiologics has made tremendous progress as a company.
  • For more information, please visit FibroBiologics' website or email FibroBiologics at [email protected].

Colossal Biosciences’ Thylacine Gene-Editing Technologies Provide Hope for Australia’s Endangered Northern Quoll

Retrieved on: 
onsdag, maj 8, 2024
Research, Environmental Issues, Environmental Health, Environment, University, Genetics, Education, Science, Biotechnology, Stem Cells, Other Science, Health, Leg, School, Organization, Deakin University, Curtin University, Ecosystem, Cell, CRISPR, Fibroblast, Colossal Biosciences, Convulsion, Risk, Genetic engineering, De-extinction, Saliva, Animal, Survival, Death, University of Melbourne, Gene editing, Doctor of Philosophy, Rhinella, Ecology, Life, Vertebrate, Food, Invertebrate, IPSC, Neurotoxin, Multimedia, Paralysis, Snake, Quoll, Reptile, Hunting

Since the introduction of invasive cane toads (Rhinella marina) in Queensland in the 1930s, the northern quolls have seen their populations plummet by 75% .

Key Points: 
  • Since the introduction of invasive cane toads (Rhinella marina) in Queensland in the 1930s, the northern quolls have seen their populations plummet by 75% .
  • Cane toads have now become an attractive food source for the northern quoll, which is especially vulnerable to the toad’s neurotoxins.
  • “It’s thrilling to see our de-extinction work for the Thylacine providing technology solutions for living endangered marsupials,” said Sara Ord, Director of Species Restoration at Colossal.
  • Colossal creates innovative technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth.

FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids

Retrieved on: 
torsdag, april 25, 2024
Conditional sentence, Cancer, Fibroblast, Communication, Trial of the century, Research, Degenerative disc disease, CDMO, Form, DNA, Therapy, Risk, Patient, Psoriasis, Charles River Laboratories, Multiple sclerosis, Wound healing, Drug discovery, Letter, Pharmaceutical industry

HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.

Key Points: 
  • HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.
  • To help advance FibroBiologics’ fibroblast-based therapies into the clinic, Charles River will conduct feasibility studies on FibroBiologics' cell manufacturing processes within its facility.
  • Additionally, contingent upon entering into a master services agreement, Charles River would serve as the contract development and manufacturing organization (CDMO) responsible for producing drug products for certain FibroBiologics’ clinical trials.
  • Combined with its legacy testing capabilities, Charles River offers a premier “concept-to-cure” advanced therapies solution.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
måndag, april 15, 2024
Sale, Idiopathic pulmonary fibrosis, Weill Cornell Medicine, University, Internal, Research and development, Epithelium, Investment, Fibroblast, Interstitial, Pleural effusion, IPF, LPE, Intensive care medicine, Administration, University of Giessen, University of Alabama, Patient, Acquisition, Fibrosis, Associate, Series, Therapy, G&A, Critical Care Medicine (journal), ALRN, Pharmaceutical industry

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • We expect to report topline results from the ongoing Phase 1b study of LTI-03 in the third quarter of this year.
  • Net Loss: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.

FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office

Retrieved on: 
torsdag, april 11, 2024
Conditional sentence, Pain, Inflammation, Fibroblast, Health, Cartilage, Communication, Trial of the century, Form, Differentiable function, Joint, Therapy, I Am the Moon, Patent, Spine, Risk, Patient, Chondrocyte, Mutation, Regenerative medicine, Proteoglycan, Regeneration, Pharmaceutical industry

Cartilage is a vital connective tissue that provides cushioning, support, and flexibility to the joints including the spine.

Key Points: 
  • Cartilage is a vital connective tissue that provides cushioning, support, and flexibility to the joints including the spine.
  • “The awarding of this patent recognizes the novelty and utility of our method for cartilage regeneration using fibroblast and other cell types.
  • It strengthens our position in fibroblast cell therapy and regenerative medicine,” said Founder & Chief Executive Officer of FibroBiologics, Pete O’Heeron.
  • These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events.